Work

CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9

Year: 2026
Type: article
Abstract: In a phase 3b trial of adults with obesity or overweight and no diabetes, both lower CagriSema dose levels were superior to placebo for bodyweight loss at 68 weeks. At week 68, mean bodyweight fell by 20.7% (1.7 mg each), 21.0% (1.0 mg each) and 2.0% (pooled placebo), efficacy estimand. Most adverse events were mild or moderate and gastrointestinal. No deaths were reported. The trial was funded by Novo Nordisk, measured weight rather than clinical outcomes, and the abstract does not report a direct comparison of the two doses. Online version: https://www.diabesityrounds.com/a/cagrisema-1-7-mg-and-1-0-mg-each-cut-bodyweight-more-than-placebo-in-redefine-9
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7234706746
FWCI:
Cites:
Cited by:
Related to: 10